Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Revolution Medicines's RMC-6236?
RMC-6236 is a small molecule commercialized by Revolution Medicines, with a leading Phase III program in Pancreatic Ductal Adenocarcinoma. According...
RMC-6236 by Revolution Medicines for Melanoma: Likelihood of Approval
RMC-6236 is under clinical development by Revolution Medicines and currently in Phase I for Melanoma. According to GlobalData, Phase I...
RMC-6236 by Revolution Medicines for Gynecological Cancer: Likelihood of Approval
RMC-6236 is under clinical development by Revolution Medicines and currently in Phase I for Gynecological Cancer. According to GlobalData, Phase...
RMC-6236 by Revolution Medicines for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
RMC-6236 is under clinical development by Revolution Medicines and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
RMC-6236 by Revolution Medicines for Non-Small Cell Lung Cancer: Likelihood of Approval
RMC-6236 is under clinical development by Revolution Medicines and currently in Phase II for Non-Small Cell Lung Cancer. According to...
RMC-6236 by Revolution Medicines for Solid Tumor: Likelihood of Approval
RMC-6236 is under clinical development by Revolution Medicines and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Revolution Medicines's RMC-6236?
RMC-6236 is a small molecule commercialized by Revolution Medicines, with a leading Phase II program in Non-Small Cell Lung Cancer....